Fabry disease (FD) is an X-linked lysosomal storage disorder caused by deficiency of a-galactosidase A enzyme. Cardiovascular (CV) disease is a common cause of mortality in FD, in particular as a result of heart failure and arrhythmia, with a significant proportion of events categorized as sudden. There are no clear models for risk prediction in FD. This systematic review aims to identify the risk factors for ventricular arrhythmia (VA) and sudden cardiac deaths (SCD) in FD. A systematic search was performed following PRISMA guidelines of EMBASE, Medline, PubMed, Web of Science, and Cochrane from inception to August 2016, focusing on identification of risk factors for the development of VA or SCD. Thirteen studies were included in the review (n = 4185 patients) from 1189 articles, with follow-up of 1.2-10 years. Weighted average age was 37.6 years, and 50% were male. Death from any cause was reported in 8.3%. Of these, 75% was due to CV problems, with the majority being SCD events (62% of reported deaths). Ventricular tachycardia was reported in 7 studies, with an average prevalence of 15.3%. Risk factors associated with SCD events were age, male gender, left ventricular hypertrophy, late gadolinium enhancement on CV magnetic resonance imaging, and non-sustained ventricular tachycardia. Although a multi-system disease, FD is a predominantly cardiac disease from a mortality perspective, with death mainly from SCD events. Limited evidence highlights the importance of clinical and imaging risk factors that could contribute to improved decision-making in the management of FD.
Introduction
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by deficiency of a galactosidase A enzyme. 1 This leads to failure to degrade glycosphingolipids and its consequent lysosomal accumulation, in particular globotriaosylceramide (Gb3) and globotriaosylsphingosine (lysoGb3), resulting in multi-system disease including progressive renal impairment, cardiomyopathy, and cerebrovascular events. The spectrum of clinical involvement is variable from severe disease in 'classical' males, predominant cardiac involvement in 'cardiac variants', to varying phenotypes in females. 2 Despite being X-linked, heterozygous females present with a similar range of clinical involvement, although typically later than hemizygous males. 3, 4 Characteristic cardiovascular (CV) features include left ventricular hypertrophy (LVH), congestive heart failure, and arrhythmia. Symptoms of palpitations and syncope are common and have been reported in up to 30% of patients. 5 Registry data have indicated that CV disease is the most common cause of death in FD (Figure 1) , although causality is difficult to determine. 6, 7 Gb3 and lysoGb3 accumulates in various cardiac cell types, including microvascular endothelium, smooth muscle cells, fibroblasts, conduction tissue and cardiomyocytes leading to a clinical picture that may mimic sarcomeric hypertrophic cardiomyopathy (HCM). In addition to the risks posed by myocardial cell hypertrophy, ischaemia, and fibrosis, glycolipid accumulation affects conduction tissue contributing to electrical instability ( Figure 2 ). 8 However, there are no clear models for risk prediction in FD, and it is specifically excluded from calculators of arrhythmic risk in HCM. 9 The purpose of this systematic review is to define the risk of ventricular arrhythmia (VA) and sudden cardiac death (SCD) in patients with FD and to identify the risk factors for these adverse events.
Methods
This systematic review was prospectively registered on PROSPERO database (CRD42016042326) and conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 10 
Literature search
Two researchers (S.B. and B.L.) performed the search independently. All studies that referenced to FD, VA, and SCD published from inception to August 2016 and available with an English language abstract were identified. Electronic search engines used included: Embase, Medline, PubMed, Web of Science, and Cochrane. Relevant Medical Subject Headings and keywords were employed, although due to the rare nature of FD, the search strategy was kept broad to ensure high sensitivity (see Supplementary material online, Table S1 ). There were no restrictions on the type of study design. The following is an example of search keywords used:
• Ventricular OR arrhythmia AND (AFD OR FD OR Anderson fabry disease OR Fabry disease OR Fabry).
• Sudden cardiac death OR death AND (AFD or FD or Anderson fabry disease or Fabry disease OR Fabry).
Study selection and eligibility criteria
The first level of filtration included the screening of titles, authors, and abstracts and was completed independently by the same two reviewers (S.B. and B.L.). Where relevant articles were identified, these were read in full by the reviewers and the references checked manually. Any additional articles identified from reviews or original articles that had not been identified in the database search were also included in the shortlist. Initial filtration removed single-person case studies, duplications of data sets and publications, reviews, and animal studies. In addition, abstracts were compared against the following inclusion criteria: (i) genotypepositive FD patients, (ii) adult age range >16 years, (iii) predominantly English language although other language articles were considered where available as English translations, and (iv) arrhythmia and/or SCD. No risk factors were required for inclusion, although risk factors were identified where possible to inform the second part of the systematic review. This resulted in a shortlist of articles, which made some reference to VA or SCD and included studies, multiple-person case series, and case reports.
Quality assessment
Each article within the final shortlist was then subjected to full evaluation of their quality by two independent reviewers (N.E. and R.S.). The articles were first reviewed to confirm eligibility and relevance of content. The Risk of Bias Assessment Tool for Non-Randomized Studies (RoBANS) was then used to assess the quality of studies in key areas including selection, performance, detection, attrition, and reporting bias (see Supplementary material online, Table S2 ). Any differences in RoBANS rating were resolved with mutual discussion and consensus among reviewers.
Data collection and analysis
Data were extracted on a standardized spreadsheet, including inclusion and exclusion criteria, patient characteristics (age, gender, and risk factors), study design (prospective or retrospective), duration of follow-up, any statistical association (e.g. univariate and/or multivariate, Cox regression analysis, hazard ratios, etc.), and endpoints (VA and SCD). Case reports were not included in data extraction or analysis, but a brief descriptive comment has been included (see Supplementary material online, Table S3 ). There were significant differences among the included studies in design and presentation, preventing any statistical methods for meta-analysis. Therefore, the data are presented qualitatively.
Results

Study selection and study characteristics
The initial search resulted in 1189 articles with 845 remaining after removal of duplicates. After abstract and title analysis, 792 articles were excluded. From the 53 articles remaining, 7 were excluded due to incomplete data sets, 8 did not meet the inclusion/exclusion criteria of this systematic review, 7 were removed because of duplication of data within the same cohort, 1 was excluded due to inclusion of paediatric patients, and 17 were categorized as case reports (see Supplementary material online, Tables S3 and S4). The remaining 13 articles were subject to full data extraction. The overall filtration process is detailed in Figure 3 . Average hazard ratios could not be calculated for the possible risk factors, because only two studies reported a hazard ratio. There was considerable variation in study type and outcomes. Twelve studies included were observational in nature, with only one being designed as an interventional trial. Only three studies [11] [12] [13] had VA or SCD as a primary endpoint, whereas in the remaining 10 studies, these were combined with other outcomes to form composite endpoints. The average follow-up ranged from 1.2 years to 10 years. Weighted mean age was 37.6 years with male/female ratio of 0.99 (2084/2101). Among studies that reported death rate on mortality, death from any cause was reported in 7.8%, death from CV causes in 5.9%, and SCD events in 4.9%. This translates into 75% of FD deaths being CV with the mode of death being categorized as SCD in most cases (62% of all reported deaths). Ventricular tachycardia was reported in 7 studies, with an average prevalence of 15.3%. Patient and study characteristics are summarized in Tables No studies have focussed on SCD events as an independent primary endpoint. The major FD registries (Fabry Registry and Fabry Outcome Survey) do not collect specific information about SCD events. From sparse single-centre data, the incidence of SCD events ranges from 0.34 to 1.4% per annum, 11, 12, 14 which is similar to that of HCM, although these data were focused on the young and there may be ascertainment bias. 21 This rate is higher than that in the nonselected general population of 0.05-0.1% per annum. 22 The frequency of malignant VA varies widely from 5 13 to 30%.
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Risk factors for sudden cardiac deaths and ventricular arrhythmia Gender FD registry data suggest that males have a reduced life expectancy compared with females (58.2 years vs. 75.5 years), with death from any cause increasing in males > _40 years and females > _60 years. 7 Data from the Fabry Registry suggest that CV-related death is the main cause of mortality in both genders (30/56 males and 5/10 females who died). 7 Two studies have identified male gender as a risk factor for SCD (11 of 14 deaths), 14, 15 but only one identified it as an independent risk factor for SCD. 14 No studies have looked specifically at the relationship between gender and VA in FD, but 2 studies found these to occur more commonly in males. In a single-centre study of 78 consecutive patients (55% male) with a mean follow-up of 1.9 years, non-sustained ventricular tachycardia (NSVT) was reported on 24-h ambulatory electrocardiographic (ECG) monitoring in 5 of the 60 patients, all of whom were male, with one subject dying suddenly. 11 In a single-centre study of the effects of enzyme replacement therapy on complications of FD in 40 patients treated for 6 years, all 6 patients who experienced SCD were male and had evidence of VA on ambulatory ECG monitoring. 15 These studies did not include multivariate analysis to take account of potential confounding factors, such as the degree of LVH.
Age
There were no studies looking at age and SCD, but three studies have specifically looked at age and CV deaths, with SCD being the Arrhythmia and sudden death in Fabry disease predominant event identified in these studies. In a single-centre study of 207 patients with 7 years follow-up, CV deaths occurred in 7 males aged over 40 years, of which five of the seven patients were classified under death due to SCD events. Age was a univariate predictor of CV death in this study. 14 The second single-centre study of FD enrolled 33 male patients at a mean age 39.2 ± 12.3 years with median 7.3 years follow-up. Cardiovascular death occurred in 7 patients, of which 5 were classified as due to VA or SCD events. 18 In the univariate analysis in this study, the odds ratio for CV death in those aged >50 years was 10.2 (1.50-69.8), compared with those <50 years. In a further study limited to 25 male FD patients with mean age 37.7 ± 10.9 years on enzyme replacement therapy followed up over 10 years, 8 CV deaths occurred, of which 6 were SCD events and all of which occurred in patients age >40 (43-49) years. 17 None of the studies specifically attributed a statistical risk of VA to age, although in one single-centre study (n = 60) with a mean followup of 1.9 years, all 5 of the 60 patients with VA were aged >40 (46-83) years. 
Left ventricular hypertrophy
Three studies have looked at the association between LVH and outcomes in FD. 14, 15, 19 In a prospective study of 207 patients from a single centre with a mean follow-up of 7.1 years investigating the clinical and genetic predictors of major CV events, total CV mortality was associated with echocardiographic LVH indexed to body surface area on multivariate analysis [hazard ratio (HR) 1.05, confidence interval (CI) 1.02 to 1.09]. 14 In a retrospective single-centre cohort study of 25 patients, all 6 patients who experienced SCD had LVH, with LV mass (calculated using the Deveraux formula by M-mode) showing a univariate association with a combined endpoint of stroke, end-stage renal disease, and death (HR 1.12, CI 1.03-1.23). 15 In a 3rd
single-centre study of mortality in 80 patients on enzyme replacement therapy, there were a total of 7 deaths over a median follow-up of 8 years. Three deaths were from SCD events and a higher LV mass index measured on echocardiography (202 ± 86 vs. 107 ± 40 g/m 2 ; P < 0.01) was associated with reduced survival on bivariate analysis. 19 Only two studies commented on any association between LVH and VA specifically. 11, 20 In a prospective single-centre study of 78 patients, a maximal wall thickness >20 mm and mean mass index 243.6 ± 102 g/m 2 measured on echocardiography were present in all 5 patients with VA.
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Late gadolinium enhancement
Late gadolinium enhancement (LGE) on CV magnetic resonance imaging (CMR) is used to characterize myocardial involvement in FD which, on histology, has been attributed to myocardial fibrosis. 23 In a post-mortem study of 7 patients with advanced cardiomyopathy, all had evidence of marked fibrosis on histology with ambulatory ECG monitoring confirming VA in all. 24 In addition, six of the seven patients had evidence of inferolateral wall thinning, a common site for late enhancement on CMR imaging in FD. The presence of LGE has been associated with an increased risk of CV mortality in large populations and in several CV diseases, including HCM, there has been interest in defining an associated risk of VA and SCD. [25] [26] [27] The evidence for LGE as a risk factor in FD comes from two studies from the same centre. In one prospective observational cohort study of 73 patients followed up for a median 4.8 ± 2.4 years, 13 of the 73 patients had VA identified on ambulatory ECG monitoring, all of whom had LGE, while none of the patients Arrhythmia and sudden death in Fabry disease without LGE had evidence of VA (Kaplan-Meier analysis: log-rank P 1 =4 0.017). 12 Furthermore, in 72 of the 73 patients with serial CMR imaging, increase in LGE over serial imaging was found to be greater in those with malignant ventricular arrhythmia, and this was the only independent predictor of VA's identified (P = 0.038). Five patients suffered an SCD event during follow-up, all of whom had LGE and prior VA. In the second study by this group, 16 patients with known cardiomyopathy on enzyme replacement therapy and evidence of LGE were monitored with implantable loop recorders and followed up for a median 1.2 (0.3-2.0) years. 16 Five patients had evidence of VA and four of these went on to have an implantable cardioverterdefibrillator (ICD).
Non-sustained ventricular tachycardia
Although NSVT was more frequent in the three studies of FD patients who died suddenly, a causal link has not been established, and statistical association is complicated by the small numbers of subjects studied. 11, 12, 15 Non-sustained ventricular tachycardia has been commonly defined in these three studies as an episode of ventricular tachycardia with a heart rate of at least 120 beats/min, lasting for at least 3 beats and persisting <30 s. In the study by Shah et al.
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(n = 60), all patients dying suddenly had previous NSVT. In the study by Kr€ amer et al., 12 two of the five patients death due to SCD previously had documented NSVT. In another study from the same group, all six patients who died due to SCD had evidence of NSVT. 15 
Chronic kidney disease
It is widely recognized that there is an increased frequency of SCD in patients with chronic kidney disease (CKD). 28 Although it is acknowledged that FD patients with CKD have an increased risk of CV events, [17] [18] [19] none of these studies were designed to establish whether this is heightened compared with the risk that exists in the non-FD CKD population. There are no data on CKD as a risk factor for VA in FD.
Symptoms
Only one study has associated the presence of symptoms in the form of palpitations and syncope with VA. 11 In the single-centre study by Shah et al., 11 5 of the 60 patients with FD followed up for a median 1.9 (0.3 to 10) years had VA detected by ambulatory ECG monitoring. Three of the 5 patients had syncope [odds ratio (OR) 24.5, 95% CI 2.9-207.3; P = 0.006] and all the five patients experienced palpitations (OR 1.4, 95% CI 1.04-1.3; P = 0.003).
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Miscellaneous
Mainz Severity Score Index score, left atrial dimension, and QRS duration were univariate predictors of cardiac death in a single study, with SCD being the predominant mode of death. 14 There is a single case series describing a family with a specific mutation (p.M187R/ g7219 T>G) in whom 4 of the 17 members died suddenly with the mode of death given as SCD. 29 
Discussion
This systematic review is the first to assess the risk of SCD and VA in FD. The main finding is that death in FD is mainly (75%) CV with SCD being the most common mode of death (62% of all reported deaths). Frustaci et al. This suggests that FD, although a multi-system disease, can be considered from a mortality perspective, a predominantly cardiac disease. Risk factors identified for SCD and VA include male gender, older age (>40 years in males), increasing LV mass index, the presence of LGE on CMR and prior NSVT. Further research is needed to determine the relative importance of each of these factors (Table 3) , with a view to the development of a risk calculator similar to that available for HCM and evidence-based guidelines for the implantation of cardioverter-defibrillators in FD. Phenotype development in FD is more age dependent than in HCM and advancing age appears to be associated with increasing risk of SCD in FD, a relationship that is less apparent in HCM. This is consistent with the current concept of FD-related cardiomyopathy as a progression from early myocardial storage to LVH and myocardial fibrosis to end-stage heart failure. 30 Although age >40 years seems to confer increased risk in men, this relationship is less clear in women and could be 10-15 years later-if it is assumed that there is a similar 'threshold' effect to the onset of VA and SCD. 6, 7 Although women present with cardiomyopathy later, they are also more likely to have evidence of LGE without LVH and the relative significance of these factors is not known. 31 More importantly, few VA and SCD have been reported in women in the existing literature and their representation may simply be a combination of the effect of the ages sampled by the studies to date and gender bias due to X-linked inheritance. 32 As better treatments emerge to manage complications of FD and improve life expectancy, this relationship may change. 33 There is evidence that LGE on CMR confers increased risk of SCD and VA in a number of CV diseases. 34 In FD, LGE is predominantly intramural or sub-epicardial, with the characteristic feature on CMR being the presence of LGE in the basal inferolateral LV, 35 correlating with marked fibrosis on histology in this region in advanced disease. 24 Moreover, there is electrophysiological evidence suggesting this region may be a source of VA. 36 In a case report of a patient with monomorphic ventricular tachycardia in FD, substrate mapping on electrophysiological studies showed that the VA arose from a lateral epicardial site. This was successfully treated by radiofrequency ablation. 36 Unlike ischaemic cardiomyopathy, it is possible that VA in FD develops from intramural or epicardial sites as seen in other nonischaemic cardiomyopathies. 37, 38 Similar to HCM, there appears to be increasing risk associated with LVH, but the hypertrophy in FD is not simply a quantitative, proportionate consequence of sphingolipid deposition. Recent data have highlighted that other factors may be important in the hypertrophic response and in the development of LGE and that these could prove to be useful biomarkers in future. First, troponin is released in FD, and it has been proposed that this represents myocyte damage and consequent replacement fibrosis. 39 Secondly, multi-parametric CMR has revealed that LGE in some patients with FD may not simply be end-stage fibrosis but also have characteristics shared with an area of acute inflammation, with disproportionately high T2 values reflecting oedema. 40 It is not yet known whether high-sensitivity troponin or an imaging biomarker such as T1/T2 mapping could be useful in predicting the risk of arrhythmia. The other risk factors identified by this systematic review are plausible but as yet lack supporting evidence. Palpitations and syncope are likely to be sensitive but are so common in patients with FD that it seems unlikely these will prove useful in a risk calculator without further clarification. 5 Involvement of the conduction system in FD is common, with shortening of the PR or PQ interval an early finding and evidenced both on electrophysiology 41 and pathology. 8 Although prolongation of the QRS duration as a risk factor for SCD and VA is widely accepted and is a key element in patient selection for device therapy, evidence in FD is lacking and further evidence is required, particularly in view of the questions raised regarding the efficacy of ICDs in non-ischaemic cardiomyopathy. 42 Non-sustained ventricular tachycardia has been widely used as a surrogate endpoint for SCD as a mode of death but this has its limitations. Although NSVT has been associated with increased incidence of SCD events, its usefulness in selecting patients for ICD is less well defined and remains a matter of ongoing research. [42] [43] [44] [45] The main limitation of this review is the absence of any randomized trials or large multi-centre collaborative studies. FD has a low prevalence and incidence, which makes randomized controlled studies difficult to perform. Most evidence comes from retrospective cohort studies without matched controls and with a high risk of bias because of a failure to consider potential confounding variables, including coronary artery disease. Two large prospective FD registries have the potential to deliver data in the volume needed to inform risk stratification but after submitting formal enquiries to both, it is clear that current results are limited by the detail and accuracy of the clinical outcomes recorded. Prospective studies using minimally invasive loop recorders may in future improve recording of arrhythmias and thereby risk stratification. This review also focused on SCD and VA, so did not investigate the risk factors for bradyarrhythmia, which may of course contribute to adverse patient outcomes. 13 
Conclusion
This systematic review highlights that FD, although a multi-system disease, can be considered from a mortality perspective a predominantly cardiac disease, with most deaths being classified as sudden events. Risk factors are older age, male gender, LVH and LGE, but further research is needed to support clinicians managing FD to improve patient prognosis.
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